Search

Your search keyword '"Im, Jin S."' showing total 303 results
Start Over Author "Im, Jin S."
303 results on '"Im, Jin S."'

1. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant

Author

Al-Juhaishi, Taha, Wang, Yingjun, Milton, Denái R., Xu-Monette, Zijun Y., Jabbour, Elias, Daher, May, Im, Jin S., Bashir, Qaiser, Iyer, Swaminathan P., Marin, David, Olson, Amanda L., Popat, Uday, Qazilbash, Muzaffar, Rondon, Gabriela, Gulbis, Alison M., Champlin, Richard E., Young, Ken H., and Khouri, Issa F.

Published
2023
Full Text
View/download PDF

2. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities

Author

Popat, Uday R., Pasvolsky, Oren, Bassett Jr., Roland, Mehta, Rohtesh S., Olson, Amanda, Chen, Julianne, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Gulbis, Alison M., Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Oran, Betul, Saini, Neeraj, Shigle, Terri Lynn, Srour, Samer A., Ramdial, Jeremy L., Rezvani, Katayoun, Qazilbash, Muzaffar H., Andersson, Borje S., Champlin, Richard E., and Shpall, Elizabeth J.

Published
2023
Full Text
View/download PDF

3. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

Author

Mehta, Rohtesh S, Bassett, Roland, Olson, Amanda, Chen, Julianne, Ahmed, Sairah, Alousi, Amin M, Anderlini, Paolo, Al-Atrash, Gheath, Bashir, Qaiser, Ciurea, Stefan O, Hosing, Chitra M, Im, Jin S, Kebriaei, Partow, Khouri, Issa, Marin, David, Molldrem, Jeffrey J, Nieto, Yago, Oran, Betul, Rezvani, Katayoun, Qazilbash, Muzaffar H, Srour, Samer A, Shpall, Elizabeth J, Andersson, Borje S, Champlin, Richard E, and Popat, Uday R

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Busulfan, Combined Modality Therapy, Female, Follow-Up Studies, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Myeloablative Agonists, Prognosis, Prospective Studies, Survival Rate, Transplantation Conditioning, Vidarabine, Immunology
Published
2019

4. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome

Author

Kongtim, Piyanuch, Parmar, Simrit, Milton, Denái R, Perez, Jorge Miguel Ramos, Rondon, Gabriela, Chen, Julianne, Chilkulwar, Abhishek R, Al-Atrash, Gheath, Alousi, Amin, Andersson, Borje S, Im, Jin S, Hosing, Chitra M, Bashir, Qaiser, Khouri, Issa, Kebriaei, Partow, Oran, Betul, Popat, Uday, Champlin, Richard, and Ciurea, Stefan O

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Pediatric, Stem Cell Research - Nonembryonic - Human, Transplantation, Stem Cell Research, Childhood Leukemia, Clinical Research, Rare Diseases, Pediatric Cancer, Hematology, Pediatric Research Initiative, Cancer, Adolescent, Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Outcomes after allogeneic stem-cell transplantation (AHSCT) are influenced by both disease- and patient-related factors. Here, we developed a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), by combining the refined disease risk index (DRI-R) and hematopoietic stem-cell transplant comorbidity/age index (HCT-CI/Age) to predict post-transplant survival for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The analysis included 942 AML/MDS patients treated with AHSCT. Patients were stratified into 4 HCT-CR risk groups: Low-risk-patients with low/intermediate DRI-R and HCT-CI/Age ≤3 (N = 272); Intermediate-risk-patients with low/intermediate DRI-R and HCT-CI/Age >3 (N = 168); High-risk-patients with high/very high DRI-R and HCT-CI/Age ≤3 (N = 284); and Very high-risk-patients with high/very high DRI-R and HCT-CI/Age >3 (N = 184). Compared with the low-risk group, intermediate, high, and very high-risk groups had a significantly increased risk of death [adjusted HR of 1.37 (P

Published
2019

5. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement

Author

Akin, Serkan, Hosing, Chitra, Khouri, Issa, Ahmed, Sairah, Alousi, Amin, Fowler, Nathan, Joseph, Jacinth, Truxillo, Jonathan, Ramdial, Jeremy L., Maadani, Farzaneh, Rondon, Gabriela, Daher, May, Im, Jin S., Steiner, Raphael, Westin, Jason, Iyer, Swaminathan P., Dabaja, Bouthaina, Anderlini, Paolo, Popat, Uday R., Qazilbash, Muzaffar H., Flowers, Christopher R., Shpall, Elizabeth, Champlin, Richard E., Nieto, Yago, and Srour, Samer A.

Published
2022
Full Text
View/download PDF

6. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

Author

Popat, Uday R, Mehta, Rohtesh S, Bassett, Roland, Chen, Julianne, Valdez, Benigno C, Kawedia, Jitesh, Ahmed, Sairah, Alousi, Amin M, Anderlini, Paolo, Al-Atrash, Geath, Bashir, Qaiser, Ciurea, Stefan O, Hosing, Chitra M, Im, Jin S, Jones, Roy, Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Parmar, Simrit, Rezvani, Katayoun, Qazilbash, Muzaffar H, Shah, Nina, Srour, Samer A, Shpall, Elizabeth J, Champlin, Richard E, and Andersson, Borje S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Transplantation, Clinical Trials and Supportive Activities, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Busulfan, Child, Comorbidity, Dose-Response Relationship, Drug, Drug Interactions, Female, Hematologic Neoplasms, Humans, Male, Middle Aged, Time Factors, Treatment Outcome, Vidarabine, Young Adult, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

BackgroundHaemopoietic stem-cell transplantation (HCT) conditioning regimens that can reduce risk of relapse without increasing non-relapse mortality are needed. We aimed to test the safety of timed-sequential delivery of low-dose versus high-dose myeloablative busulfan in older patients and patients with comorbidities.MethodsThis non-stratified, open-label, randomised phase 2 trial was done at The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Patients with haematological cancers aged between 5 and 75 years were eligible to participate in the study. Patients who had HIV or uncontrollable infections were excluded. Eligible patients were randomly assigned (1:1 by a computer-generated programme in block sizes of four) to receive a total intravenous busulfan dose to achieve an area under the curve of 16 000 μmol/min (16K group) or 20 000 μmol/min (20K group) on the basis of pharmacokinetic analysis, plus intravenous fludarabine 40 mg/m2 for 4 days. The investigators and the research nurses were masked to the block size to conceal allocation. The primary outcome was day 100 non-relapse mortality. All analyses were by modified intention to treat, including only patients who received at least one dose of the study drug. No interim analyses were planned and accrual is complete. This study is registered with ClinicalTrials.gov, number NCT01572662.FindingsBetween April 18, 2012, and Dec 9, 2015, 98 patients were enrolled. 49 patients were randomly assigned to the 16K group and 49 to the 20K group, one of which was removed from the study before starting the intervention. Median age was 60 years (IQR 54-67). 50 (52%) patients had an HCT-specific comorbidity index score of 3 or more, and 41 (42%) had a high or very high Disease Risk Index score. Day 100 non-relapse mortality was 4% (95% CI 0-10) in the 16K group and 6% (0-13) in the 20K group (p=0·65). Infection was the most common grade 3-5 toxicity in both the 20K group (25 [52%] of 48 patients) and the 16K group (24 [49%] of 49 participants). Mucositis (nine [19%] of 48 patients vs three [6%] of 49 patients), idiopathic pneumonia syndrome (nine [19%] of 48 patients vs two [4%] of 49 patients), and culture-negative neutropenic fever (16 [33%] of 48 patients vs eight [16%] of 49 patients) were more common in the 20K group than in the 16K group.InterpretationMyeloablative doses of busulfan administered in a timed-sequential manner with fludarabine is associated with low non-relapse mortality in older patients and patients with comorbidities. Additional studies are required to show whether this approach can reduce the risk of relapse.FundingCancer Center Support Grant (US National Cancer Institute, National Institutes of Health).

Published
2018

7. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease

Author

Im, Jin S, Abraham, Susan C, Saliba, Rima M, Rondon, Gabriela, Ross, William A, Rashid, Asif, Shpall, Elizabeth J, Popat, Uday, Qazilbash, Muzaffar H, Hosing, Chitra, Oran, Betul, Shah, Nina, Tewari, Priti, Nieto, Yago, Kebriaei, Partow, Champlin, Richard E, and Alousi, Amin M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Cancer, Transplantation, Digestive Diseases, Rare Diseases, Clinical Research, Good Health and Well Being, Adolescent, Adult, Aged, Biopsy, Bone Marrow Transplantation, Chi-Square Distribution, Child, Child, Preschool, Cord Blood Stem Cell Transplantation, Endoscopy, Gastrointestinal, Female, Gastrointestinal Diseases, Gastrointestinal Tract, Graft vs Host Disease, Hematologic Neoplasms, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Peripheral Blood Stem Cell Transplantation, Predictive Value of Tests, Prognosis, Retrospective Studies, Risk Factors, Severity of Illness Index, Young Adult, prognostic value, histologic grade 1, gastrointestinal graft versus host disease, Pathology, Clinical sciences
Abstract

Histologic confirmation is considered a standard practice to diagnose gastrointestinal graft versus host disease (GI GVHD) and is often used in making treatment decisions. A histologic grade is often determined in cases that are diagnosed with GI GVHD. Although extensive crypt loss (histologic grade 4) is associated with high nonrelapse mortality (NRM), the prognostic value for the more common grade 1 is poorly understood. As clinical decisions are made on the degree of histologic evidence, it is important to establish its prognostic significance. Therefore, we evaluated 309 patients who underwent endoscopic biopsy for suspected GI GVHD within 6 months posttransplant between 2009 and 2012. The presence of histologic grade 1 was associated with increased NRM (hazard ratio=2.7, P=0.02) when compared with one of negative biopsy in patients with lower but not isolated upper GI GVHD. Multivariate competing-risk regression analysis confirmed the independent impact of histologic grade 1 in patients with early clinical stages of lower GI GVHD (stage 0 to 2) (hazard ratio=2.7, P=0.044). When compared with advanced histologic grades, histologic grade 1 did not lessen the adverse outcome for patients with advanced lower GI GVHD (stage 3 to 4) (cumulative incidence NRM of 84%). In conclusion, the presence of histologic grade 1 is associated with increased NRM in patients presenting with lower GI GVHD (stages 0 to 2) and is sufficient evidence for decision to initiate therapy. At the same time, histologic grade 1 does not lessen the markedly adverse impact of advanced lower GI GVHD (stage 3 to 4) and is not synonymous with "mild" GVHD.

Published
2017

8. Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial.

Author

Khouri, Issa F., Alzahrani, Kamal, Kantarjian, Hagop, Milton, Denái R., Gulbis, Alison M., Sasaki, Koji, Jain, Nitin, Short, Nicholas J., Kadia, Tapan, Daher, May, Rafei, Hind, Im, Jin S., Marin, David, Olson, Amanda L., Popat, Uday, Qazilbash, Muzaffar, Ramdial, Jeremy, Rondon, Gabriela, Srour, Samer, and Kebriaei, Partow

Published
2024
Full Text
View/download PDF

9. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide

Author

Mehta, Rohtesh S., Saliba, Rima M., Ghanem, Sassine, Alousi, Amin M., Rondon, Gabriela, Anderlini, Paolo, Al-Atrash, Gheath, Bashir, Qaiser, Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Popat, Uday R., Qazilbash, Muzaffar H., Ramdial, Jeremy, Saini, Neeraj, Srour, Samer A., Champlin, Richard E., Rezvani, Katayoun, and Shpall, Elizabeth J.

Published
2022
Full Text
View/download PDF

12. P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES

Author

Popat, Uday R., primary, Lontos, Konstantinos, additional, Bassett, Roland, additional, Kawedia, Jitesh, additional, Valdez, Ben C., additional, Gulbis, Alison, additional, Alousi, Amin M., additional, Al-Atrash, Gheath, additional, Bashir, Qaiser, additional, Hosing, Chitra M., additional, Im, Jin S., additional, Kebriaei, Partow, additional, Khouri, Issa, additional, Marin, David, additional, Mehta, Rohtesh S., additional, Nieto, Yago, additional, Oran, Betul, additional, Olson, Amanda, additional, Qazilbash, Muzaffar H., additional, Ramdial, Jeremy L., additional, Saini, Neeraj, additional, Srour, Samer A., additional, Kadia, Tapan, additional, Daver, Naval, additional, Short, Nicholas, additional, Rezvani, Katayoun, additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Andersson, Borje S., additional

Published
2023
Full Text
View/download PDF

13. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide

Author

Mehta, Rohtesh S., Saliba, Rima M., Alsfeld, Leonard C., Jorgensen, Jeffrey L., Wang, Sa A., Anderlini, Paolo, Al-Atrash, Gheath, Bashir, Qaiser, Ciurea, Stefan O., Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Popat, Uday R., Qazilbash, Muzaffar H., Ramdial, Jeremy, Rondon, Gabriela, Saini, Neeraj, Srour, Samer A., Rezvani, Katayoun, Shpall, Elizabeth J., Champlin, Richard E., and Alousi, Amin M.

Published
2021
Full Text
View/download PDF

14. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial

Author

Mehta, Rohtesh S., Bassett, Roland, Chen, Julianne, Valdez, Benigno C., Kawedia, Jitesh, Alousi, Amin M., Anderlini, Paolo, Al-Atrash, Gheath, Bashir, Qaiser, Ciurea, Stefan O., Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Qazilbash, Muzaffar H., Ramdial, Jeremy, Saini, Neeraj, Srour, Samer A., Rezvani, Katayoun, Shpall, Elizabeth J., Andersson, Borje S., Champlin, Richard E., and Popat, Uday R.

Published
2021
Full Text
View/download PDF

15. Figure S4 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Author

Lee, Sung-Eun, primary, Wang, Feng, primary, Grefe, Maison, primary, Trujillo-Ocampo, Abel, primary, Ruiz-Vasquez, Wilfredo, primary, Takahashi, Koichi, primary, Abbas, Hussein A., primary, Borges, Pamella, primary, Antunes, Dinler Amaral, primary, Al-Atrash, Gheath, primary, Daver, Naval, primary, Molldrem, Jeffrey J., primary, Futreal, Andrew, primary, Garcia-Manero, Guillermo, primary, and Im, Jin S., primary

Published
2023
Full Text
View/download PDF

16. Data from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Author

Lee, Sung-Eun, primary, Wang, Feng, primary, Grefe, Maison, primary, Trujillo-Ocampo, Abel, primary, Ruiz-Vasquez, Wilfredo, primary, Takahashi, Koichi, primary, Abbas, Hussein A., primary, Borges, Pamella, primary, Antunes, Dinler Amaral, primary, Al-Atrash, Gheath, primary, Daver, Naval, primary, Molldrem, Jeffrey J., primary, Futreal, Andrew, primary, Garcia-Manero, Guillermo, primary, and Im, Jin S., primary

Published
2023
Full Text
View/download PDF

17. Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Author

Lee, Sung-Eun, primary, Wang, Feng, primary, Grefe, Maison, primary, Trujillo-Ocampo, Abel, primary, Ruiz-Vasquez, Wilfredo, primary, Takahashi, Koichi, primary, Abbas, Hussein A., primary, Borges, Pamella, primary, Antunes, Dinler Amaral, primary, Al-Atrash, Gheath, primary, Daver, Naval, primary, Molldrem, Jeffrey J., primary, Futreal, Andrew, primary, Garcia-Manero, Guillermo, primary, and Im, Jin S., primary

Published
2023
Full Text
View/download PDF

18. Table S1-7 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Author

Lee, Sung-Eun, primary, Wang, Feng, primary, Grefe, Maison, primary, Trujillo-Ocampo, Abel, primary, Ruiz-Vasquez, Wilfredo, primary, Takahashi, Koichi, primary, Abbas, Hussein A., primary, Borges, Pamella, primary, Antunes, Dinler Amaral, primary, Al-Atrash, Gheath, primary, Daver, Naval, primary, Molldrem, Jeffrey J., primary, Futreal, Andrew, primary, Garcia-Manero, Guillermo, primary, and Im, Jin S., primary

Published
2023
Full Text
View/download PDF

19. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Author

Lee, Sung-Eun, primary, Wang, Feng, additional, Grefe, Maison, additional, Trujillo-Ocampo, Abel, additional, Ruiz-Vasquez, Wilfredo, additional, Takahashi, Koichi, additional, Abbas, Hussein A., additional, Borges, Pamella, additional, Antunes, Dinler Amaral, additional, Al-Atrash, Gheath, additional, Daver, Naval, additional, Molldrem, Jeffrey J., additional, Futreal, Andrew, additional, Garcia-Manero, Guillermo, additional, and Im, Jin S., additional

Published
2023
Full Text
View/download PDF

20. Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation

Author

Popat, Uday R., primary, Saliba, Rima M., additional, Mehta, Rohtesh S., additional, Alousi, Amin M., additional, Al-Atrash, Gheath, additional, Bashir, Qaiser, additional, Hosing, Chitra M., additional, Gulbis, Alison M., additional, Im, Jin S., additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Kawedia, Jitesh D., additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Ramdial, Jeremy, additional, Saini, Neeraj Y., additional, Shigle, Terri Lynn, additional, Srour, Samer A., additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Andersson, Borje S., additional, Shpall, Elizabeth J., additional, and Champlin, Richard E., additional

Published
2023
Full Text
View/download PDF

21. Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation

Author

Popat, Uday R., primary, Saliba, Rima M., additional, Mehta, Rohtesh S., additional, Alousi, Amin M., additional, Al-Atrash, Gheath, additional, Bashir, Qaiser, additional, Chen, Julianne, additional, Gulbis, Alison M., additional, Hosing, Chitra M., additional, Im, Jin S., additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Kawedia, Jitesh D., additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Ramdial, Jeremy, additional, Saini, Neeraj Y., additional, Srour, Samer A., additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Kantarjian, Hagop, additional, Andersson, Borje S., additional, Champlin, Richard E., additional, and Shpall, Elizabeth J., additional

Published
2023
Full Text
View/download PDF

22. Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30

Author

Khouri, Issa F., primary, Hwang, Hyunsoo, additional, Neelapu, Sattva S., additional, Wang, Xuemei, additional, Hosing, Chitra, additional, Ahmed, Sairah, additional, Kebriaei, Partow, additional, Daher, May, additional, Olson, Amanda L., additional, Anderlini, Paolo, additional, Im, Jin S., additional, Westin, Jason, additional, Shpall, Elizabeth J, additional, Champlin, Richard E, additional, and Nastoupil, Loretta J., additional

Published
2022
Full Text
View/download PDF

24. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

Author

Agbedia, Owhofasa O., primary, Prakash, Rishab, additional, Xu, Jie, additional, Becnel, Melody R., additional, Nair, Ranjit, additional, Steiner, Raphael E, additional, Feng, Lei, additional, Lee, Hun Ju, additional, Strati, Paolo, additional, Ahmed, Sairah, additional, Parmar, Simrit, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Westin, Jason, additional, Nastoupil, Loretta J., additional, Vo, Ann, additional, Samaniego, Felipe, additional, Fowler, Nathan H., additional, Saini, Neeraj, additional, Khouri, Issa F., additional, Im, Jin S., additional, Fayad, Luis, additional, Jain, Preetesh, additional, Wang, Michael L., additional, Miranda, Roberto N., additional, Vega, Francisco, additional, Medeiros, Jeffrey, additional, Oki, Yasuhiro, additional, Flowers, Christopher R., additional, Neelapu, Sattva S., additional, and Iyer, Swaminathan P., additional

Published
2022
Full Text
View/download PDF

25. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies

Author

Singh, Harjeet, primary, Srour, Samer A., additional, Milton, Denái R., additional, McCarty, Jessica, additional, Dai, Cuiping, additional, Gaballa, Mahmoud R., additional, Ammari, Mariam, additional, Olivares, Simon, additional, Huls, Helen, additional, De Groot, Eleanor, additional, Marin, David, additional, Petropoulos, Demetrios, additional, Olson, Amanda L., additional, Anderlini, Paolo, additional, Im, Jin S., additional, Khouri, Issa, additional, Hosing, Chitra M., additional, Rezvani, Katayoun, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, Cooper, Laurence J. N., additional, and Kebriaei, Partow, additional

Published
2022
Full Text
View/download PDF

26. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study

Author

Popat, Uday R., primary, Andersson, Borje S, additional, Bassett, Roland, additional, Kawedia, Jitesh, additional, Valdez, Ben C., additional, Alousi, Amin M., additional, Al-Atrash, Gheath, additional, Bashir, Qaiser, additional, Hosing, Chitra M., additional, Im, Jin S., additional, Kebriaei, Partow, additional, Marin, David, additional, Nieto, Yago, additional, Oran, Betul, additional, Olson, Amanda, additional, Qazilbash, Muzaffar H., additional, Srour, Samer A., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Mehta, Rohtesh S., additional

Published
2022
Full Text
View/download PDF

28. Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide

Author

Mehta, Rohtesh S., Saliba, Rima M., Ghanem, Sassine, Alousi, Amin M., Rondon, Gabriela, Anderlini, Paolo, Al-Atrash, Gheath, Bashir, Qaiser, Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Popat, Uday R., Qazilbash, Muzaffar H., Ramdial, Jeremy, Saini, Neeraj, Srour, Samer A., Champlin, Richard E., Rezvani, Katayoun, and Shpall, Elizabeth J.

Subjects
Leukemia, Myeloid, Acute, Transplantation Conditioning, Siblings, Transplantation, Haploidentical, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Humans, Cyclophosphamide, Article
Abstract

With the use of post-transplantation cyclophosphamide (PTCy), the outcomes of mismatched related donor hematopoietic cell transplantation (HCT) are now approaching those of matched donor HCT. Here we compared haploidentical donor HCT versus HLA-matched unrelated donor (MUD) HCT and HLA-identical sibling donor (MSD) HCT in a cohort in which all patients received PTCy for graft-versus-host disease (GVHD) prophylaxis. We included 661 patients (275 haploidentical, 246 MUD, and 140 MSD HCT). The most common diagnoses were acute myelogenous leukemia and myelodysplastic syndrome. In multivariate analysis, the haploidentical group was found to have significantly higher nonrelapse mortality (NRM) (hazard ratio [HR], 3.2; 95% confidence interval [CI], 2 to 4.9; P.001) and inferior progression-free survival (HR, 1.8; 95% CI, 1.4 to 2.4; P.001) and overall survival (OS; HR, 2.2; 95% CI, 1.6 to 3; P.001) compared with the MUD group. Relapse was the most common cause of death in all groups. Among causes of NRM, the haploidentical group had more infection-related deaths and fewer GVHD-related deaths than the other groups. The haploidentical group also had a higher risk of viral and fungal infections, grade ≥3 hemorrhagic cystitis, and cardiovascular toxicities and slower reconstitution of CD4, CD8, and regulatory T cells but faster reconstitution of natural killer cells. In an exploratory analysis, older patients with older donors (50 years for both) appeared to have particularly high NRM and lower OS in the haploidentical group compared with the other groups. Our data suggest that even with the use of PTCy, the outcomes of haploidentical HCT are inferior to those of HLA-matched donor HCT.

Published
2022

29. Structural reorganization of the antigen-binding groove of human CD1b for presentation of mycobacterial sulfoglycolipids

Author

Garcia-Alles, Luis F., Collmann, Anthony, Versluis, Cees, Lindner, Buko, Guiard, Julie, Maveyraud, Laurent, Huc, Emilie, Im, Jin S., Sansano, Sebastiano, Brando, Thérèse, Julien, Sylviane, Prandi, Jacques, Gilleron, Martine, Porcelli, Steven A., de la Salle, Henri, Heck, Albert J. R., Mori, Lucia, Puzo, Germain, Mourey, Lionel, and De Libero, Gennaro

Published
2011

30. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

Author

Popat, Uday R., primary, Bassett, Roland, additional, Thall, Peter F., additional, Alousi, Amin M., additional, Alatrash, Gheath, additional, Bashir, Qaiser, additional, Hosing, Chitra, additional, Im, Jin S., additional, Kebriaei, Partow, additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda L., additional, Oran, Betul, additional, Ramdial, Jeremy L., additional, Saini, Neeraj, additional, Srour, Samer A., additional, Valdez, Benigno C., additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Daver, Naval, additional, Ravandi, Farhad, additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, Andersson, Borje S., additional, and Mehta, Rohtesh S., additional

Published
2021
Full Text
View/download PDF

31. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial

Author

Popat, Uday R., primary, Mehta, Rohtesh S., additional, Bassett, Roland, additional, Alousi, Amin M., additional, Alatrash, Gheath, additional, Bashir, Qaiser, additional, Hosing, Chitra, additional, Im, Jin S., additional, Kebriaei, Partow, additional, Kawedia, Jitesh D., additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda L., additional, Oran, Betul, additional, Ramdial, Jeremy L., additional, Saini, Neeraj, additional, Srour, Samer A., additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Shpall, Elizabeth J., additional, Andersson, Borje S., additional, and Champlin, Richard E., additional

Published
2021
Full Text
View/download PDF

32. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

Author

Popat, Uday R., primary, Mehta, Rohtesh S., additional, Bassett, Roland, additional, Alousi, Amin M., additional, Alatrash, Gheath, additional, Bashir, Qaiser, additional, Hosing, Chitra, additional, Im, Jin S., additional, Kebriaei, Partow, additional, Gulbis, Alison, additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda L., additional, Oran, Betul, additional, Ramdial, Jeremy L., additional, Saini, Neeraj, additional, Srour, Samer A., additional, Valdez, Benigno C., additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Kadia, Tapan M., additional, Konopleva, Marina, additional, Shpall, Elizabeth J., additional, Andersson, Borje S., additional, and Champlin, Richard E., additional

Published
2021
Full Text
View/download PDF

33. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial

Author

Popat, Uday R., primary, Mehta, Rohtesh S., additional, Bassett, Roland, additional, Alousi, Amin M., additional, Alatrash, Gheath, additional, Bashir, Qaiser, additional, Hosing, Chitra, additional, Im, Jin S., additional, Kebriaei, Partow, additional, Kawedia, Jitesh D., additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda L., additional, Oran, Betul, additional, Ramdial, Jeremy L., additional, Saini, Neeraj, additional, Srour, Samer A., additional, Valdez, Benigno C., additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Kadia, Tapan M., additional, Kantarjian, Hagop, additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Andersson, Borje S., additional

Published
2021
Full Text
View/download PDF

34. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

Author

Olson, Amanda, primary, Lin, Ruitao, additional, Marin, David, additional, Rafei, Hind, additional, Bdaiwi, Mustafa H., additional, Thall, Peter F., additional, Basar, Rafet, additional, Abudayyeh, Ala, additional, Banerjee, Pinaki, additional, Aung, Fleur M., additional, Kaur, Indresh, additional, Abueg, Glorette, additional, Rao, Sheetal, additional, Chemaly, Roy, additional, Mulanovich, Victor, additional, Al-Atrash, Gheath, additional, Alousi, Amin M., additional, Andersson, Borje S., additional, Anderlini, Paolo, additional, Bashir, Qaiser, additional, Castro, Karla M., additional, Daher, May, additional, Galvan, Isabel M., additional, Hosing, Chitra, additional, Im, Jin S., additional, Jones, Roy B., additional, Kebriaei, Partow, additional, Khouri, Issa, additional, Mehta, Rohtesh, additional, Molldrem, Jeffrey, additional, Nieto, Yago, additional, Oran, Betul, additional, Popat, Uday, additional, Qazilbash, Muzaffar, additional, Rondon, Gabriela, additional, Saini, Neeraj, additional, Spencer, Bryan, additional, Srour, Samer, additional, Washington, Dominique, additional, Barnett, Melissa, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, and Rezvani, Katayoun, additional

Published
2021
Full Text
View/download PDF

35. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant

Author

Khouri, Issa F., primary, Milton, Denái R., additional, Gulbis, Alison M., additional, Jabbour, Elias J., additional, Nastoupil, Loretta, additional, Ledesma, Celina, additional, Anderlini, Paolo, additional, Bashir, Qaiser, additional, Daher, May, additional, Im, Jin S., additional, Iyer, Swaminathan P., additional, Marin, David, additional, Mehta, Rohtesh S., additional, Olson, Amanda L., additional, Popat, Uday R., additional, Qazilbash, Muzaffar, additional, Saini, Neeraj, additional, Samaniego, Felipe, additional, Rondon, Gabriela, additional, Medeiros, L. Jeffrey, additional, and Champlin, Richard E., additional

Published
2021
Full Text
View/download PDF

36. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Author

Khouri, Issa F., Alzahrani, Kamal, Gulbis, Alison, Sasaki, Koji, Jain, Nitin, Short, Nicholas J., Kadia, Tapan M., Daher, MD, May, Rafei, Hind, Im, Jin S, Marin, David, Olson, Amanda L., Popat, Uday R., Qazilbash, Muzaffar H., Ramdial, Jeremy, Rondon, Gabriela, Srour, Samer A., Kebriaei, Partow, Shpall, Elizabeth J., Kantarjian, Hagop M., Champlin, Richard E., and Jabbour, Elias

Published
2023
Full Text
View/download PDF

37. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies

Author

Khouri, Issa F., Gruschkus, Stephen K., Gulbis, Alison, Ledesma, Celina, Jain, Nitin, Kadia, Tapan M., Pemmaraju, Naveen, Anderlini, Paolo, Bashir, Qaiser, Daher, May, Kebriaei, Partow, Marin, David, Mehta, Rohtesh, Popat, Uday R., Saini, Neeraj, Srour, Samer A., Im, Jin S., Fayad, Luis, Nair, Ranjit, Iyer, Swaminathan P, Strati, Paolo, Samaniego, Felipe, Nastoupil, Loretta J., Flowers, Christopher, Rondon, Gabriela, Kantarjian, Hagop M., Champlin, Richard E., and Jabbour, Elias

Published
2020
Full Text
View/download PDF

39. Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Author

Abbas, Hussein A, Hao, Dapeng, Tomczak, Katarzyna, Barrodia, Praveen, Im, Jin S., Reville, Patrick K, Alaniz, Zoe, Wang, Wei, Wang, Ruiping, Wang, Feng, Takahashi, Koichi, Ning, Jing, Ding, Maomao, Matthews, Jairo A., Little, Latasha, Zhang, Jianhua, Basu, Sreyashi, DiNardo, Courtney D., Kadia, Tapan M., Ravandi, Farhad, Borthakur, Gautam, Konopleva, Marina, Garcia-Manero, Guillermo, Green, Michael R, Alatrash, Gheath, Sharma, Padmanee, Allison, James P, Kornblau, Steven M., Rai, Kunal, Wang, Linghua, Futreal, P Andrew, and Daver, Naval

Published
2020
Full Text
View/download PDF

42. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications

Author

Kim, Sang T., primary, Sheshadri, Ajay, additional, Shannon, Vickie, additional, Kontoyiannis, Dimitrios P., additional, Kantarjian, Hagop, additional, Garcia-Manero, Guillermo, additional, Ravandi, Farhad, additional, Im, Jin S., additional, Boddu, Prajwal, additional, Bashoura, Lara, additional, Balachandran, Diwakar D., additional, Evans, Scott E., additional, Faiz, Saadia, additional, Ruiz Vazquez, Wilfredo, additional, Divenko, Margarita, additional, Mathur, Rohit, additional, Tippen, Samantha P., additional, Gumbs, Curtis, additional, Neelapu, Sattva S., additional, Naing, Aung, additional, Wang, Linghua, additional, Diab, Adi, additional, Futreal, Andrew, additional, Nurieva, Roza, additional, and Daver, Naval, additional

Published
2021
Full Text
View/download PDF

43. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of [alpha]-galactosylceramides

Author

Yu, Karl O.A., Im, Jin S., Molano, Alberto, Dutronc, Yves, Illarionov, Petr A., Forestier, Claire, Fujiwara, Nagatoshi, Arias, Isa, Miyake, Sachiko, Yamamura, Takashi, Chang, Young-Tae, Besra, Gurdyal S., and Porcelli, Steven A.

Subjects
T cells -- Research, Cytokines -- Research, Immune response -- Regulation, Immune response -- Research, Science and technology
Abstract

A form of [alpha]-galactosylceramide, KRN7000, activates CD1d-restricted V[alpha]14-invariant (V[alpha]14i) natural killer (NK) T cells and initiates multiple downstream immune reactions. We report that substituting the C26:0 N-acyl chain of KRN7000 with shorter, unsaturated fatty acids modifies the outcome of V[alpha]14i NKT cell activation. One analogue containing a diunsaturated C20 fatty acid (C20:2) potently induced a T helper type 2-biased cytokine response, with diminished IFN-[gamma] production and reduced V[alpha]14i NKT cell expansion. C20:2 also exhibited less stringent requirements for loading onto CD1d than KRN7000, suggesting a mechanism for the immunomodulatory properties of this lipid. The differential cellular response elicited by this class of V[alpha]14i NKT cell agonists may prove to be useful in immunotherapeutic applications. cytokines | inflammation I autoimmunity | immunoregulation

Published
2005

44. 215 - Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation

Author

Popat, Uday R., Saliba, Rima M., Mehta, Rohtesh S., Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Hosing, Chitra M., Gulbis, Alison M., Im, Jin S., Kebriaei, Partow, Khouri, Issa F., Kawedia, Jitesh D., Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Ramdial, Jeremy, Saini, Neeraj Y., Shigle, Terri Lynn, Srour, Samer A., Rezvani, Katayoun, Qazilbash, Muzaffar H., Andersson, Borje S., Shpall, Elizabeth J., and Champlin, Richard E.

Published
2023
Full Text
View/download PDF

45. 212 - Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation

Author

Popat, Uday R., Saliba, Rima M., Mehta, Rohtesh S., Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Chen, Julianne, Gulbis, Alison M., Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa F., Kawedia, Jitesh D., Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Ramdial, Jeremy, Saini, Neeraj Y., Srour, Samer A., Rezvani, Katayoun, Qazilbash, Muzaffar H., Kantarjian, Hagop, Andersson, Borje S., Champlin, Richard E., and Shpall, Elizabeth J.

Published
2023
Full Text
View/download PDF

47. Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation

Author

Oran, Betul, primary, Alatrash, Gheath, additional, Alousi, Amin M., additional, Mehta, Rohtesh S., additional, Hosing, Chitra, additional, Popat, Uday R., additional, Im, Jin S., additional, McCarty, Jessica M, additional, Ramos, Jennifer D, additional, Keer, Harold N., additional, Thall, Peter F, additional, and Champlin, Richard E., additional

Published
2020
Full Text
View/download PDF

48. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)

Author

Iyer, Swami P., primary, Xu, Jie, additional, Becnel, Melody R., additional, Nair, Ranjit, additional, Steiner, Raphael, additional, Feng, Lei, additional, Lee, Hun Ju, additional, Strati, Paolo, additional, Ahmed, Sairah, additional, Parmar, Simrit, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Westin, Jason, additional, Nastoupil, Loretta J., additional, Vo, Ann, additional, Samaniego, Felipe, additional, Fowler, Nathan H., additional, Saini, Neeraj, additional, Khouri, Issa F., additional, Im, Jin S., additional, Jain, Preetesh, additional, Fayad, Luis, additional, Wang, Michael, additional, Miranda, Roberto N., additional, Vega, Francisco, additional, Flowers, Christopher, additional, and Neelapu, Sattva S., additional

Published
2020
Full Text
View/download PDF

49. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma

Author

Khouri, Issa F., primary, Gruschkus, Stephen K., additional, Ledesma, Celina, additional, Anderlini, Paolo, additional, Bashir, Qaiser, additional, Daher, May, additional, Iyer, Swami P., additional, Marin, David, additional, Mehta, Rohtesh, additional, Olson, Amanda L., additional, Popat, Uday R., additional, Samaniego, Felipe, additional, Qazilbash, Muzaffar H., additional, Im, Jin S., additional, Rondon, Gabriela, additional, Champlin, Richard E., additional, Gulbis, Alison, additional, and Young, Ken H., additional

Published
2020
Full Text
View/download PDF

50. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy

Author

Mukherjee, Akash, primary, Milton, Denái R., additional, Jabbour, Elias, additional, Daver, Naval, additional, Gulbis, Alison, additional, Ledesma, Celina, additional, Konopleva, Marina, additional, DiNardo, Courtney D., additional, Ravandi, Farhad, additional, Kadia, Tapan M., additional, Alatrash, Gheath, additional, Alousi, Amin M., additional, Daher, May, additional, Marin, David, additional, Olson, Amanda L., additional, Oran, Betul, additional, Kebriaei, Partow, additional, Saini, Neeraj, additional, Srour, Samer A., additional, Popat, Uday R., additional, Im, Jin S., additional, Mehta, Rohtesh, additional, Rondon, Gabriela, additional, Kantarjian, Hagop M., additional, Champlin, Richard E., additional, and Khouri, Issa F., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results